+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 70Years
All Genders
Healthy Volunteers
ID06934252

Safety and Effects of TRB-061 Injections in Healthy Adults and Patients With Moderate-to-Severe Atopic Dermatitis A Phase 1a1b Controlled Study

Led by TRex Bio, Inc. · Updated on 2026-10-28

115

Participants Needed

19

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, how the body processes, and the effects of a new drug called TRB-061, given as injections under the skin, in healthy adults and people with moderate-to-severe atopic dermatitis AD. This Phase 1a1b study includes healthy volunteers and patients to explore different dosing schedules and amounts in a randomized, double-blind, placebo-controlled setting. The study has three parts Part 1 involves healthy adults receiving a single dose of TRB-061 or placebo Part 2 includes healthy adults receiving three doses every 4 weeks over 8 weeks and Part 3 involves participants with moderate-to-severe AD receiving four doses every 4 weeks over 12 weeks. In Part 3, participants may also opt to switch treatments after the first period. Placebo doses match the appearance and schedule of TRB-061. Participants will attend multiple visits for dosing and follow-up, including safety checks, blood tests to measure drug levels, and assessments of side effects up to 12 weeks after dosing in Part 1, 10 weeks after dosing in Part 2, and through the end of the study in Part 3. Researchers will track adverse events, drug levels in the blood, and responses to treatment during the study, which runs until early 2028.

CONDITIONS

Brief Title

Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis

Research Team

S

Study Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here